Documento di consenso ANMCO/ELAS/SIBioC: Raccomandazioni sull'impiego dei biomarcatori cardiaci nello scompenso cardiaco

Marcello Ciaccio, Nadia Aspromonte, Massimo Iacoviello, Gianfranco Misuraca, Roberto Latini, Michele Emdin, Andrea Mortara, Mauro Feola, Roberto Valle, Aldo Clerico, Serge Masson, Marco Migliardi, Alberto Aimo, Claudio Passino, Michele Massimo Gulizia, Giuseppe Di Tano

Risultato della ricerca: Article

4 Citazioni (Scopus)

Abstract

Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention. Natriuretic peptides (B-type natriuretic peptide [BNP] and N-terminal proBNP) are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks promising. In the last few years, an array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: myocardial insult, inflammation, fibrosis and remodeling, but their role in the clinical care of the patient is still partially defined and more studies are needed before to be well validated. Moreover, several new biomarkers have the potential to identify patients with early renal dysfunction and appear to have promise to help the management cardio-renal syndrome. With different biomarkers reflecting HF presence, the various pathways involved in its progression, as well as identifying unique treatment options for HF management, a closer cardiologist-laboratory link, with a multi-biomarker approach to the HF patient, is not far ahead, allowing the unique opportunity for specifically tailoring care to the individual pathological phenotype.
Lingua originaleItalian
pagine (da-a)615-656
Numero di pagine42
RivistaGiornale Italiano di Cardiologia
Volume17
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cita questo

Ciaccio, M., Aspromonte, N., Iacoviello, M., Misuraca, G., Latini, R., Emdin, M., ... Di Tano, G. (2016). Documento di consenso ANMCO/ELAS/SIBioC: Raccomandazioni sull'impiego dei biomarcatori cardiaci nello scompenso cardiaco. Giornale Italiano di Cardiologia, 17, 615-656.

Documento di consenso ANMCO/ELAS/SIBioC: Raccomandazioni sull'impiego dei biomarcatori cardiaci nello scompenso cardiaco. / Ciaccio, Marcello; Aspromonte, Nadia; Iacoviello, Massimo; Misuraca, Gianfranco; Latini, Roberto; Emdin, Michele; Mortara, Andrea; Feola, Mauro; Valle, Roberto; Clerico, Aldo; Masson, Serge; Migliardi, Marco; Aimo, Alberto; Passino, Claudio; Gulizia, Michele Massimo; Di Tano, Giuseppe.

In: Giornale Italiano di Cardiologia, Vol. 17, 2016, pag. 615-656.

Risultato della ricerca: Article

Ciaccio, M, Aspromonte, N, Iacoviello, M, Misuraca, G, Latini, R, Emdin, M, Mortara, A, Feola, M, Valle, R, Clerico, A, Masson, S, Migliardi, M, Aimo, A, Passino, C, Gulizia, MM & Di Tano, G 2016, 'Documento di consenso ANMCO/ELAS/SIBioC: Raccomandazioni sull'impiego dei biomarcatori cardiaci nello scompenso cardiaco', Giornale Italiano di Cardiologia, vol. 17, pagg. 615-656.
Ciaccio, Marcello ; Aspromonte, Nadia ; Iacoviello, Massimo ; Misuraca, Gianfranco ; Latini, Roberto ; Emdin, Michele ; Mortara, Andrea ; Feola, Mauro ; Valle, Roberto ; Clerico, Aldo ; Masson, Serge ; Migliardi, Marco ; Aimo, Alberto ; Passino, Claudio ; Gulizia, Michele Massimo ; Di Tano, Giuseppe. / Documento di consenso ANMCO/ELAS/SIBioC: Raccomandazioni sull'impiego dei biomarcatori cardiaci nello scompenso cardiaco. In: Giornale Italiano di Cardiologia. 2016 ; Vol. 17. pagg. 615-656.
@article{5d5320b6fd1840228415d17a08dde13b,
title = "Documento di consenso ANMCO/ELAS/SIBioC: Raccomandazioni sull'impiego dei biomarcatori cardiaci nello scompenso cardiaco",
abstract = "Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention. Natriuretic peptides (B-type natriuretic peptide [BNP] and N-terminal proBNP) are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks promising. In the last few years, an array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: myocardial insult, inflammation, fibrosis and remodeling, but their role in the clinical care of the patient is still partially defined and more studies are needed before to be well validated. Moreover, several new biomarkers have the potential to identify patients with early renal dysfunction and appear to have promise to help the management cardio-renal syndrome. With different biomarkers reflecting HF presence, the various pathways involved in its progression, as well as identifying unique treatment options for HF management, a closer cardiologist-laboratory link, with a multi-biomarker approach to the HF patient, is not far ahead, allowing the unique opportunity for specifically tailoring care to the individual pathological phenotype.",
author = "Marcello Ciaccio and Nadia Aspromonte and Massimo Iacoviello and Gianfranco Misuraca and Roberto Latini and Michele Emdin and Andrea Mortara and Mauro Feola and Roberto Valle and Aldo Clerico and Serge Masson and Marco Migliardi and Alberto Aimo and Claudio Passino and Gulizia, {Michele Massimo} and {Di Tano}, Giuseppe",
year = "2016",
language = "Italian",
volume = "17",
pages = "615--656",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",

}

TY - JOUR

T1 - Documento di consenso ANMCO/ELAS/SIBioC: Raccomandazioni sull'impiego dei biomarcatori cardiaci nello scompenso cardiaco

AU - Ciaccio, Marcello

AU - Aspromonte, Nadia

AU - Iacoviello, Massimo

AU - Misuraca, Gianfranco

AU - Latini, Roberto

AU - Emdin, Michele

AU - Mortara, Andrea

AU - Feola, Mauro

AU - Valle, Roberto

AU - Clerico, Aldo

AU - Masson, Serge

AU - Migliardi, Marco

AU - Aimo, Alberto

AU - Passino, Claudio

AU - Gulizia, Michele Massimo

AU - Di Tano, Giuseppe

PY - 2016

Y1 - 2016

N2 - Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention. Natriuretic peptides (B-type natriuretic peptide [BNP] and N-terminal proBNP) are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks promising. In the last few years, an array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: myocardial insult, inflammation, fibrosis and remodeling, but their role in the clinical care of the patient is still partially defined and more studies are needed before to be well validated. Moreover, several new biomarkers have the potential to identify patients with early renal dysfunction and appear to have promise to help the management cardio-renal syndrome. With different biomarkers reflecting HF presence, the various pathways involved in its progression, as well as identifying unique treatment options for HF management, a closer cardiologist-laboratory link, with a multi-biomarker approach to the HF patient, is not far ahead, allowing the unique opportunity for specifically tailoring care to the individual pathological phenotype.

AB - Biomarkers have dramatically impacted the way heart failure (HF) patients are evaluated and managed. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention. Natriuretic peptides (B-type natriuretic peptide [BNP] and N-terminal proBNP) are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and a natriuretic peptide-guided HF management looks promising. In the last few years, an array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: myocardial insult, inflammation, fibrosis and remodeling, but their role in the clinical care of the patient is still partially defined and more studies are needed before to be well validated. Moreover, several new biomarkers have the potential to identify patients with early renal dysfunction and appear to have promise to help the management cardio-renal syndrome. With different biomarkers reflecting HF presence, the various pathways involved in its progression, as well as identifying unique treatment options for HF management, a closer cardiologist-laboratory link, with a multi-biomarker approach to the HF patient, is not far ahead, allowing the unique opportunity for specifically tailoring care to the individual pathological phenotype.

UR - http://hdl.handle.net/10447/217931

UR - http://www.giornaledicardiologia.it/r.php?v=2448&a=25658&l=328078&f=allegati/02448_2016_09/fulltext/01%20Aspromonte%20(615-656).pdf

M3 - Article

VL - 17

SP - 615

EP - 656

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

ER -